Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interrupting Prolonged Sitting With Periodic Interval Exercise: Effect on Postprandial Lipemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04241081
Recruitment Status : Not yet recruiting
First Posted : January 27, 2020
Last Update Posted : January 27, 2020
Sponsor:
Information provided by (Responsible Party):
University of Texas at Austin

Brief Summary:
Investigating the effects of interrupting various lengths of prolonged sitting with bike sprints on post prandial lipemia the next day. We will conduct three trials, one control, one with two-hour sitting intervals (total of 4 bouts of bike sprints) and one with 6-hour sitting intervals I total of two bouts of bike sprints). A milkshake high fat tolerance test will be conducted the next day and whole body fat oxidation as well as triglyceride area under the curve will be measured every hour for the duration of the 6-hour test.

Condition or disease Intervention/treatment Phase
Sedentary Behavior Hypertriglyceridemia Behavioral: Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Interrupting Prolonged Sitting With Periodic Interval Exercise: Effect on Postprandial Lipemia
Estimated Study Start Date : January 2020
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Control group-no exercise
A no-exercise control. Must maintain <4,500 steps per day for 3 consecutive days followed by a high fat tolerance test on day 4.
Experimental: Exercise intervention 1
Two consecutive days of <4,500 steps per day followed by an intervention day on day 3. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 2 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
Behavioral: Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia
This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.

Experimental: Exercise intervention 2
Two consecutive days of <4,500 steps per day followed by an intervention day. Intervention day consists of interrupting 8-hour sit with bike sprint protocol every 6 hours. Participants must aim to maintain <2,500 steps on intervention day. A high fat tolerance test will be performed the following day on day 4.
Behavioral: Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia
This is a behavioral intervention designed to determine the effect of breaking up prolonged bouts of sitting every 2 hours and every 6 hours with 5 sets of 4 second bouts of maximum effort bicycle ergometer accelerations compared to sitting alone on the blood triglyceride response and whole body fat oxidation after a high fat meal.




Primary Outcome Measures :
  1. Triglyceride area under the curve [ Time Frame: 6 hour long high fat tolerance test ]
    Blood measurements baseline and every hour during a high fat tolerance test.


Secondary Outcome Measures :
  1. Whole body fat oxidation [ Time Frame: 10 min, baseline, 2 hours post ingestion of shake, 4 hours, 6 hours. ]
    Expired gas collection and measurement of expired gas concentrations in mass spectrometer, baseline and every two hours during high fat tolerance test.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Inactive or recreational healthy adults aged 18-65 years old.

Exclusion Criteria:

  • Lactose intolerance, cardiovascular or metabolic diagnoses, medications for cardiovascular or metabolic diagnoses, orthopedic issues barring cycling.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04241081


Contacts
Layout table for location contacts
Contact: Rebecca braden, BS 4422156656 rebecca.braden@utexas.edu
Contact: Edward Coyle, PhD 512 471 8596 coyle@austin.utexas.edu

Locations
Layout table for location information
United States, Texas
University of Texas, Austin
Austin, Texas, United States, 78705
Contact: Rebecca Braden, BS    442-215-6656    rebecca.braden@utexas.edu   
Contact: Edward Coyle, PhD    512 471 8596    coyle@austin.utexas.edu   
Sponsors and Collaborators
University of Texas at Austin
Layout table for additonal information
Responsible Party: University of Texas at Austin
ClinicalTrials.gov Identifier: NCT04241081    
Other Study ID Numbers: 2019-10-0091
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertriglyceridemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases